104 research outputs found
Supplemental material for Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline
No full textSupplemental Material for Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline by Catharina JM Klijn, Maurizio Paciaroni, Eivind Berge, Eleni Korompoki, Janika Kõrv, Avtar Lal, Jukka Putaala and David J Werring in European Stroke Journal</p
sj-docx-1-eso-10.1177_23969873221109405 – Supplemental material for Sinus rhythm restoration and improved outcomes in patients with acute ischemic stroke and in-hospital paroxysmal atrial fibrillation
No full textSupplemental material, sj-docx-1-eso-10.1177_23969873221109405 for Sinus rhythm restoration and improved outcomes in patients with acute ischemic stroke and in-hospital paroxysmal atrial fibrillation by Dimitrios Sagris, Eleni Korompoki, George Ntaios, Stylianos Tzeis, Efstathios Manios, John Kanakakis, Haralampos Milionis, Panagiotis Papanagiotou, George Andrikopoulos, Gregory YH Lip and Konstantinos Vemmos in European Stroke Journal</p
sj-docx-1-wso-10.1177_17474930221109149 – Supplemental material for Efficacy and safety of vitamin-K antagonists and direct oral anticoagulants for stroke prevention in patients with heart failure and sinus rhythm: An updated systematic review and meta-analysis of randomized clinical trials
No full textSupplemental material, sj-docx-1-wso-10.1177_17474930221109149 for Efficacy and safety of vitamin-K antagonists and direct oral anticoagulants for stroke prevention in patients with heart failure and sinus rhythm: An updated systematic review and meta-analysis of randomized clinical trials by Weijia Li, Jiyoung Seo, Damianos G Kokkinidis, Leonidas Palaiodimos, Sanjana Nagraj, Eleni Korompoki, Haralambos Milionis, Wolfram Doehner, Gregory Y. H. Lip and George Ntaios in International Journal of Stroke</p
sj-docx-1-wso-10.1177_17474930221109149 – Supplemental material for Efficacy and safety of vitamin-K antagonists and direct oral anticoagulants for stroke prevention in patients with heart failure and sinus rhythm: An updated systematic review and meta-analysis of randomized clinical trials
No full textSupplemental material, sj-docx-1-wso-10.1177_17474930221109149 for Efficacy and safety of vitamin-K antagonists and direct oral anticoagulants for stroke prevention in patients with heart failure and sinus rhythm: An updated systematic review and meta-analysis of randomized clinical trials by Weijia Li, Jiyoung Seo, Damianos G Kokkinidis, Leonidas Palaiodimos, Sanjana Nagraj, Eleni Korompoki, Haralambos Milionis, Wolfram Doehner, Gregory Y. H. Lip and George Ntaios in International Journal of Strok
Detection of atrial fibrillation after stroke due to large or small vessel disease: systematic review and meta-analysis
No full textBackground: Emerging evidence indicates a frequent occurrence of atrial fibrillation (AF) detection among patients with established causes of ischemic stroke unrelated to AF. This systematic review and meta-analysis aimed to evaluate AF detection rates in stroke patients with large or small vessel disease, considering the AF detection modality and duration of cardiac rhythm monitoring. Aims: We conducted a comprehensive search of PubMed and Scopus databases up to March 2, 2024, to identify randomized controlled trials, non-randomized prospective studies, and retrospective studies assessing the frequency of AF detection in stroke patients with large or small vessel disease. The primary outcome of interest was the rate of AF detection. We utilized inverse-variance weights to produce the pooled prevalence (effect size-ES) and 95% confidence interval (CI) of patients diagnosed with post-stroke AF. Summary of review: In the analysis of 14 eligible studies encompassing 4,334 patients, AF was identified in 154 out of 2,082 patients with strokes attributed to small or large-vessel disease, yielding a pooled prevalence of 6.27% (ES; 95% confidence interval [CI]: 3.18-10.17, I2=87.83%). Among patients with large-vessel disease strokes, AF was diagnosed in 79 out of 1,042 patients, accounting for a pooled prevalence of 5.07% (ES;95% CI: 1.30-10.33, I2=77.05%). Similarly, among those with small-vessel disease strokes, AF was detected in 75 out of 1,040 patients, with a pooled prevalence of 5.03% (ES; 95% CI: 1.96-9.06, I2=78.05%). Conclusions: AF is often found in ischemic stroke patients with large or small-vessel disease. Detection rates increase with longer cardiac rhythm monitoring. The safety and benefits of oral anticoagulation for these AF episodes are uncertain
Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation : A European Stroke Organisation guideline
No full textPatients with ischemic stroke or transient ischemic attack and non-valvular atrial fibrillation have a high risk of recurrent stroke and other vascular events. The aim of this guideline is to provide recommendations on antithrombotic medication for secondary prevention of stroke and other vascular outcomes in these patients. The working group identified questions and outcomes, graded evidence, and developed recommendations according to the Grading of Recommendations Assessment, Development, and Evaluation approach and the European Stroke Organisation (ESO) standard operating procedure for guidelines. The guideline was reviewed and approved by the ESO guideline board and the ESO executive committee. In patients with atrial fibrillation and previous stroke or transient ischemic attack, oral anticoagulants reduce the risk of recurrence over antiplatelets or no antithrombotic treatment. Non-vitamin K antagonist oral anticoagulants are preferred over vitamin K antagonists because they have a lower risk of major bleeding and death. Recommendations are weak regarding timing of treatment, (re-)starting oral anticoagulants in patients with previous intracerebral haemorrhage, and treatment in specific patient subgroups of those of older age, with cognitive impairment, renal failure or small vessel disease, because of a lack of strong evidence. In conclusion, for patients with atrial fibrillation and ischemic stroke or transient ischemic attack, non-vitamin K antagonist oral anticoagulants are the preferred treatment for secondary prevention of recurrent stroke or thromboembolism. Further research is required to determine the best timing for initiating oral anticoagulants after an acute ischemic stroke, whether or not oral anticoagulants should be (re)started in patients with a history of intracerebral haemorrhage, and the best secondary preventive treatment in specific subgroups.Peer reviewe
ESO893512 Supplemental Material2 - Supplemental material for SiPP (Stroke in Pregnancy and Postpartum): A prospective, observational, international, multicentre study on pathophysiological mechanisms, clinical profile, management and outcome of cerebrovascular diseases in pregnant and postpartum women
No full textSupplemental material, ESO893512 Supplemental Material2 for SiPP (Stroke in Pregnancy and Postpartum): A prospective, observational, international, multicentre study on pathophysiological mechanisms, clinical profile, management and outcome of cerebrovascular diseases in pregnant and postpartum women by Svetlana Lorenzano, Christine Kremer, Aleksandra Pavlovic, Dejana R Jovanovic, Else Charlotte Sandset, Hanne Christensen, Cheryl Bushnell, Anita Arsovska, Nikola Sprigg, Christine Roffe, Petra Ijäs, Zuzana Gdovinova, Anne Alexandrov, Marialuisa Zedde, Rossana Tassi, Monica Acciaresi, Maria Lantz, Katharina Sunnerhagen, Marija Zarkov, Kirsi Rantanen, Fabienne Perren, Helle K Iversen, Christina Kruuse, Agnieszka Slowik, Paola Palazzo, Janika Korv, Annette Fromm, Arijana Lovrencic-Huzjan, Eleni Korompoki, Ana Catarina Fonseca, Seana L Gall, Freimuth Brunner, Valeria Caso, Simona Sacco and for the SiPP Trial Investigators and ESO-WISE Group in European Stroke Journal</p
ESO893512 Supplemental Material1 - Supplemental material for SiPP (Stroke in Pregnancy and Postpartum): A prospective, observational, international, multicentre study on pathophysiological mechanisms, clinical profile, management and outcome of cerebrovascular diseases in pregnant and postpartum women
No full textSupplemental material, ESO893512 Supplemental Material1 for SiPP (Stroke in Pregnancy and Postpartum): A prospective, observational, international, multicentre study on pathophysiological mechanisms, clinical profile, management and outcome of cerebrovascular diseases in pregnant and postpartum women by Svetlana Lorenzano, Christine Kremer, Aleksandra Pavlovic, Dejana R Jovanovic, Else Charlotte Sandset, Hanne Christensen, Cheryl Bushnell, Anita Arsovska, Nikola Sprigg, Christine Roffe, Petra Ijäs, Zuzana Gdovinova, Anne Alexandrov, Marialuisa Zedde, Rossana Tassi, Monica Acciaresi, Maria Lantz, Katharina Sunnerhagen, Marija Zarkov, Kirsi Rantanen, Fabienne Perren, Helle K Iversen, Christina Kruuse, Agnieszka Slowik, Paola Palazzo, Janika Korv, Annette Fromm, Arijana Lovrencic-Huzjan, Eleni Korompoki, Ana Catarina Fonseca, Seana L Gall, Freimuth Brunner, Valeria Caso, Simona Sacco and for the SiPP Trial Investigators and ESO-WISE Group in European Stroke Journal</p
ESO863606 Supplemental Material - Supplemental material for Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11–13 November 2018
No full textSupplemental material, ESO863606 Supplemental Material for Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11–13 November 2018 by Niaz Ahmed, Heinrich Audebert, Guillaume Turc, Charlotte Cordonnier, Hanne Christensen, Simona Sacco, Else Charlotte Sandset, George Ntaios, Andreas Charidimou, Danilo Toni, Christian Pristipino, Martin Köhrmann, Joji B Kuramatsu, Götz Thomalla, Robert Mikulik, Gary A Ford, Joan Martí-Fàbregas, Urs Fischer, Magnus Thoren, Erik Lundström, Gabriel JE Rinkel, H Bart van der Worp, Marius Matusevicius, Georgios Tsivgoulis, Haralampos Milionis, Marta Rubiera, Robert Hart, Tiago Moreira, Maria Lantz, Christina Sjöstrand, Grethe Andersen, Peter Schellinger, Konstantinos Kostulas, Katharina Stibrant Sunnerhagen, Boris Keselman, Eleni Korompoki, Jan Purrucker, Pooja Khatri, William Whiteley, Eivind Berge, Michael Mazya, Diederik WJ Dippel, Satu Mustanoja, Mads Rasmussen, Åsa Kuntze Söderqvist, Irene Escudero-Martínez and Thorsten Steiner in European Stroke Journal</p
In patients with ESUS, the effects of OAC and antiplatelet therapy on recurrent ischemic stroke differ across subgroups at 1 to 5 y
No full text- …
